The Recall Desk
HighFDA (Devices)·Z-1035-2024·Announced 2024-02-14

BD BBL Moxifloxacin Test Discs Recalled for Susceptibility Testing Inaccuracy

BD BBL Sensi Disc Moxifloxacin test discs are recalled due to possible failures in antibiotic susceptibility testing accuracy. Test failures could lead to delayed diagnosis or inappropriate antibiotic selection.

What this means for you

Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.

Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. As a risk-of-harm product where injury has not yet been reported, it meets the criterion for High severity per the rubric.

Plain-English summary

BD BBL Sensi Disc Moxifloxacin-5 ug is a laboratory diagnostic test disc used for antibiotic susceptibility testing of H. influenzae. Becton Dickinson & Co. has recalled 2,363,168 units distributed domestically nationwide and internationally.

The recall addresses a possibility of reproducibility, accuracy, and quality control failures in the antibiotic susceptibility testing process. Test failures could result in product discard, delayed test results, or adverse diagnostic outcomes including delayed diagnosis, inappropriate antibiotic selection, or extended antibiotic treatment duration.

The recalled product

Product
BD BBL Sensi Disc Moxifloxacin- 5 ug, used for semi-quantitative in vitro susceptibility testing. Catalog Number 231758¿
Manufacturer
Becton Dickinson & Co.
Hazard
  • diagnostic-inaccuracy
  • delayed-diagnosis
  • inappropriate-antibiotic

Distribution

Distributed nationwide across the United States.